Roles of phosphatidylinositol-3-kinases signaling pathway in inflammation-related cancer: Impact of rs10889677 variant and buparlisib in colitis-associated cancer

Figure 4 The body weight changes. A: Percentage of weight loss (%) in all groups. A drop in body weight was seen in the colitis-associated cancer (CAC) group after every cycle of dextran sodium sulphate (DSS) induction. Red arrows indicate the cycle of DSS induction. Two-way ANOVA was employed; n = 8; B: Total mean body weight loss (g) between buparlisib-treated and -untreated CAC-induced mice group. ^aP < 0.05 (compared to the CAC untreated group); data are presented as mean ± SEM; student T-test was employed; n = 4. CAC: Colitis-associated cancer; CRC: Colorectal cancer.